Journal
NATURE MEDICINE
Volume 14, Issue 11, Pages 1236-1246Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.1877
Keywords
-
Funding
- NIAMS NIH HHS [P01 AR048564-02, P01 AR048564-02S1, P01 AR048564-03, P01 AR048564, P01 AR048564-01A10001, P01 AR048564-01A1, AR36820, P01 AR048564-050003, P01 AR048564-05, P01 AR048564-050004, R01 AR036820, P01 AR048564-04, AR48564] Funding Source: Medline
Ask authors/readers for more resources
Infantile hemangiomas are localized and rapidly growing regions of disorganized angiogenesis. We show that expression of vascular endothelial growth factor receptor-1 (VEGFR1) in hemangioma endothelial cells (hemECs) and hemangioma tissue is markedly reduced compared to controls. Low VEGFR1 expression in hemECs results in VEGF-dependent activation of VEGFR2 and downstream signaling pathways. In hemECs, transcription of the gene encoding VEGFR1 (FLT1) is dependent on nuclear factor of activated T cells ( NFAT). Low VEGFR1 expression in hemECs is caused by reduced activity of a pathway involving beta 1 integrin, the integrin-like receptor tumor endothelial marker-8 (TEM8), VEGFR2 and NFAT. In a subset of individuals with hemangioma, we found missense mutations in the genes encoding VEGFR2 (KDR) and TEM8 (ANTXR1). These mutations result in increased interactions among VEGFR2, TEM8 and b1 integrin proteins and in inhibition of integrin activity. Normalization of the constitutive VEGFR2 signaling in hemECs with soluble VEGFR1 or antibodies that neutralize VEGF or stimulate b1 integrin suggests that local administration of these or similar agents may be effective in hemangioma treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available